These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1400933)

  • 1. The effect of gonadotrophin-releasing hormone (GnRH) agonist in the follicular phase on in-vitro fertilization outcome in normo-ovulatory women.
    Smitz J; Van Den Abbeel E; Bollen N; Camus M; Devroey P; Tournaye H; Van Steirteghem AC
    Hum Reprod; 1992 Sep; 7(8):1098-102. PubMed ID: 1400933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization.
    Beckers NG; Laven JS; Eijkemans MJ; Fauser BC
    Hum Reprod; 2000 Jan; 15(1):43-9. PubMed ID: 10611186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced implantation rate associated with a subtle rise in serum progesterone concentration during the follicular phase of cycles stimulated with a combination of a gonadotrophin-releasing hormone agonist and gonadotrophin.
    Harada T; Yoshida S; Katagiri C; Takao N; Ikenari T; Toda T; Mio Y; Terakawa N
    Hum Reprod; 1995 May; 10(5):1060-4. PubMed ID: 7657741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of gonadotrophin-releasing hormone agonist on follicular development in patients with polycystic ovary syndrome in an in-vitro fertilization and embryo transfer programme.
    Gersak K; Meden-Vrtovec H; Tomazevic T
    Hum Reprod; 1994 Sep; 9(9):1596-9. PubMed ID: 7836506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is continuation of a gonadotrophin-releasing hormone agonist (GnRHa) necessary for women at risk of developing the ovarian hyperstimulation syndrome?
    Wada I; Matson PL; Horne G; Buck P; Lieberman BA
    Hum Reprod; 1992 Sep; 7(8):1090-3. PubMed ID: 1400932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
    Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T
    Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized placebo-controlled double-blind study.
    Younis JS; Simon A; Koren R; Dorembus D; Schenker JG; Laufer N
    Fertil Steril; 1992 Sep; 58(3):575-80. PubMed ID: 1387849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of Buserelin to human menopausal gonadotrophins in patients with failed stimulations for IVF or GIFT.
    Smitz J; Devroey P; Camus M; Khan I; Staessen C; Van Waesberghe L; Wisanto A; Van Steirteghem AC
    Hum Reprod; 1988 Oct; 3 Suppl 2():35-8. PubMed ID: 3147990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of a short regimen of buserelin, a gonadotrophin-releasing hormone agonist, and human menopausal gonadotrophin in assisted conception cycles.
    Owen EJ; Davies MC; Kingsland CR; Jacobs HS; Mason BA
    Hum Reprod; 1989 Oct; 4(7):749-53. PubMed ID: 2514192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term utilization of a gonadotropin-releasing hormone agonist (buserelin) for induction of ovulation in an in vitro fertilization program.
    Loumaye E; de Cooman S; Anoma M; Psalti I; Depreester S; Schmit M; Thomas K
    Ann N Y Acad Sci; 1988; 541():96-102. PubMed ID: 3143299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midluteal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization.
    Urbancsek J; Witthaus E
    Fertil Steril; 1996 May; 65(5):966-71. PubMed ID: 8612858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization.
    MacLachlan V; Besanko M; O'Shea F; Wade H; Wood C; Trounson A; Healy DL
    N Engl J Med; 1989 May; 320(19):1233-7. PubMed ID: 2496310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term use of buserelin in combination with human menopausal gonadotrophins for ovarian stimulation for in-vitro fertilization in endocrinologically normal women.
    Smitz J; Bollen N; Camus M; Devroey P; Wisanto A; Van Steirteghem AC
    Hum Reprod; 1990 Feb; 5(2):157-62. PubMed ID: 2108989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Premature luteinization is not eliminated by pituitary desensitization with leuprolide acetate in women undergoing gonadotrophin stimulation who demonstrated premature luteinization in a prior gonadotrophin-only cycle.
    Hofmann GE; Bergh PA; Guzman I; Masuku S; Navot D
    Hum Reprod; 1993 May; 8(5):695-8. PubMed ID: 8314961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro fertilization for women with pure tubal occlusion: the impact of short gonadotropin-releasing hormone agonist treatment.
    Luxman D; Cohen JR; Lessing JB; Yovel I; David MP; Ami A
    Fertil Steril; 1995 Feb; 63(2):357-60. PubMed ID: 7843443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison between a standard and reduced dose of D-Trp-6-luteinizing hormone-releasing hormone administered after pituitary suppression for in-vitro fertilization.
    Simon A; Benshushan A; Shushan A; Zajicek G; Dorembus D; Lewin A; Laufer N
    Hum Reprod; 1994 Oct; 9(10):1813-7. PubMed ID: 7844208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of smoking on oocyte quality and hormonal parameters of patients undergoing in vitro fertilization-embryo transfer.
    Weigert M; Hofstetter G; Kaipl D; Gottlich H; Krischker U; Bichler K; Poehl M; Feichtinger W
    J Assist Reprod Genet; 1999 Jul; 16(6):287-93. PubMed ID: 10394523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased progesterone/estradiol ratio on the day of HCG administration adversely affects success of in vitro fertilization-embryo transfer in patients stimulated with gonadotropin-releasing hormone agonist and recombinant follicle-stimulating hormone.
    Ou YC; Lan KC; Chang SY; Kung FT; Huang FJ
    Taiwan J Obstet Gynecol; 2008 Jun; 47(2):168-74. PubMed ID: 18603501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme.
    Smith EM; Anthony FW; Gadd SC; Masson GM
    BMJ; 1989 Jun; 298(6686):1483-6. PubMed ID: 2503080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of HMG/HCG superovulation for AID with or without superactive GnRH agonist.
    Gerris J; Jacquemyn Y; Desmedt E; Delbeke L; Buytaert P
    Hum Reprod; 1989 Nov; 4(8):937-40. PubMed ID: 2515211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.